Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold
Get Alerts THLD Hot Sheet
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Stifel downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Buy to Hold after the company announced negative topline data from both of its Phase III trials for TH-302 in pancreatic cancer and sarcoma.
Analyst Thomas Shrader commented, "Despite very positive phase II data, the pancreatic cancer again narrowly missed the OS endpoint (HR=0.84). The sarcoma trial showed no treatment effect. Based on the overwhelming preclinical data that TH-302 was reaching and penetrating tumors with an active chemotherapy we believe these results cast significant doubt on the fundamental focus of Threshold’s pipeline. The company currently has about $56.4 million in cash and this forms the basis of our valuation."
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $3.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Dassault Systemes SE (DSY:FP) (DASTY) to Neutral
- Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'
- Hilton Worldwide (HLT) PT Raised to $205 at Macquarie, 'we await a better entry point'
Create E-mail Alert Related Categories
Analyst Comments, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!